Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model.
RSV continues to be a high priority for vaccine and antiviral drug development. Unfortunately, no safe and effective RSV vaccine is available and treatment options are limited. Over the past decade, several studies have focused on the role of RSV G protein on viral entry, viral neutralization, and RSV-mediated pathology. Anti-G murine monoclonal antibody (mAb) 131-2G treatment has been previously shown to reduce weight loss, bronchoalveolar lavage (BAL) cell number, airway reactivity, and Th2-type cytokine production in RSV-infected mice more rapidly than a commercial humanized monoclonal antibody (mAb) against RSV F protein (Palivizumab). In this study, we have tested two human anti-RSV G mAbs, 2B11 and 3D3, by both prophylactic and therapeutic treatment for RSV in the BALB/c mouse model. Both anti-G mAbs reduced viral load, leukocyte infiltration and IFN-γ and IL-4 expression in cell-free BAL supernatants emphasizing the potential of anti-G mAbs as anti-inflammatory and antiviral strategies.
['Caidi|Hayat|H|', 'Miao|Congrong|C|', 'Thornburg|Natalie J|NJ|', 'Tripp|Ralph A|RA|', 'Anderson|Larry J|LJ|', 'Haynes|Lia M|LM|']
D000818:Animals D061067:Antibodies, Monoclonal, Humanized D000914:Antibodies, Viral D000998:Antiviral Agents D004195:Disease Models, Animal D005260:Female D008168:Lung D051379:Mice D008807:Mice, Inbred BALB C D011014:Pneumonia D018357:Respiratory Syncytial Virus Infections D018113:Respiratory Syncytial Virus, Human D013047:Specific Pathogen-Free Organisms D019562:Viral Load
Virus RSV Monoclonal antibody G protein CX3C CX3CR1 Pathogenesis